

The generation of candidate for atopic dermatitis via selective STAT3 inhibition

JW C&C Research Laboratories



IMMUNOLOGY	Candidate
Product Type	Chemical – Small Molecule
Indication	1st Indication: Atopic Dermatitis
Target	Signal Transducer and Activator of Transcription 3 (STAT3)
MoA(Mechanism of Action)	Directly binding to STAT3 → Inhibition of STAT3 activation → Reduction of pruritus- and inflammation-related cytokines in AD
Competitiveness	<p>First in Class</p> <ul style="list-style-type: none"> • The inhibitors of JAK kinases showed side effects such as heart-related events, serious infection, cancer, and thrombosis due to the suppression of the various upper immune responses. • By selectively blocking the activation of STAT3, the lowest signal of the JAK/STAT signaling pathway involved in inflammation and pruritus in atopic dermatitis, it aims to secure competitiveness as a safe drug with similar efficacy to JAK inhibitors, but with minimal side effects.
Development Stage	Candidate
Route of Administration	Oral Administration